Concepedia
Statistics
Publications
15
Citations
3.1K
H-Index
14
Active since
1999
Affiliations
Pfizer (United States)(Current)
Pfizer (United Kingdom)
Utah State University
UC San Diego Health System
California Institute for Biomedical Research
Charlotte Allerton is an author at Pfizer (United States) specializing in pharmacology, drug discovery, and pharmacy.
Publications per year
1999–2025
An oral SARS-CoV-2 M <sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19
Dafydd R. Owen, Charlotte Allerton, Annaliesa S. Anderson et al. · Science · 2021 · 1.9K citations · Full text
Medicine, Infectious Diseases, Pharmacology +13
Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)
Manthena V. S. Varma, Stefanus J. Steyn, Charlotte Allerton et al. · Pharmaceutical Research · 2015 · 311 citations
Pharmacy, Pharmacokinetics, Pharmacology +14
Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19
Britton Boras, Rhys Jones, Brandon J. Anson et al. · Nature Communications · 2021 · 296 citations · Full text
Pharmacy, Infectious Diseases, Pharmacology +15
Discovery of a Novel Inhibitor of Coronavirus 3CL Protease for the Potential Treatment of COVID-19
Britton Boras, Rhys Jones, Brandon J. Anson et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2020 · 159 citations · Full text
Pharmacy, Medicinal Chemistry, Pharmacology +17
A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19
Charlotte Allerton, Joel T. Arcari, Lisa Aschenbrenner et al. · Journal of Medicinal Chemistry · 2024 · 73 citations · Full text
Medicine, Infectious Diseases, Pharmacology +15
1–5 of 15